Clinical Trial Detail

NCT ID NCT01610284
Title Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)r
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements yes
Sponsors Novartis Pharmaceuticals

Her2-receptor negative breast cancer


Buparlisib + Fulvestrant


Age Groups: senior adult

Additional content available in CKB BOOST